
TLDR Biotech
All the top biotech and pharma industry updates, straight to your inbox in only one email. Trusted by 1700+ biotech and pharma professionals.
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | February 6 - 9, 2025
Bain Capital acquires Mitsubishi Tanabe Pharma for $3.3B, CSL Behring's Hemgenix delivers positive four year Ph3 follow-up data, Sionna Therapeutics raises $191M in IPO to fuel cystic fibrosis drugs, Olix Pharmaceuticals & Eli Lilly part on developing MASH hopefuly OLX702A (targeting MARC1 gene), Bioluminescence Ventures abruptly shuts down after 15 months and raising $477M + 33 more stories

Biotech & Pharma Updates | February 5 - 6, 2025
AstraZeneca shares rise after announcing potential (and manageable) $4.5M fine to resolve Chinese probe into actions of former employees, Eli Lilly reports doubled Q4 profits driven by diabetes and obesity drug sales, Immuneering & Regeneron partner to test IMM-1-104 and Libtayo combo in RAS-mutant lung cancer, Viracta Therapeutics shuts down operations, Trump administration reportedly planning major layoffs across multiple HHS-related federal health agencies + 28 more stories

Biotech & Pharma Updates | February 4 - 5, 2025
GSK raises 2031 revenue forecast by £2B (from £38B to £40B), Valneva's chikungunya virus vaccine lands MHRA (UK) approval, Harvard Medical School's personalized cancer vaccine delivers promising Ph1 data in renal cell carcinoma, Novo Nordisk's monlunabant falls flat in diabetic kidney disease Ph2, USDA discovers a new circulating H5N1 bird flu strain in Nevada dairy herds + 30 more stories

Biotech & Pharma Updates | February 3 - 4, 2025
Pfizer moves past pandemic volatility with "stronger-than-expected" COVID product sales in Q4, Genentech scores FDA approval for Susvimo mAb fragment in diabetic macular edema, Akribion Therapeutics launches with €8M seed funding to develop RNA-guided cell depletion tech, Turnstone Biologics begins the dreaded “strategic alternatives” search, China targets Illumina in retaliation for U.S. tariffs + 24 more stories

Biotech & Pharma Updates | February 2 - 3, 2025
United Therapeutics' gene-edited pig kidneys cleared for Ph1, Australian radiopharma AdvanCell scores a $112M Series C, NSF resumes payments after five-day freeze but uncertainty remains, epigenomic-medicine biotech Omega Therapeutics says they're weeks away from bankruptchy, Trump's new tariffs could increase generic drug prices for Americans + 35 more stories

Biotech & Pharma Updates | January 30 - February 2, 2025
Novartis has big spending plans for bolt-on acquisitions in 2025, FDA approves Celltrion's Avtozma (Actemra biosimilar), AbbVie raises 2027 sales forecast as Skyrizi and Rinvoq continue to perform, AstraZeneca cancels planned £450M ($559M) Liverpool vaccine facility due to reduced UK government funding, CDC removes youth survey data on sexual orientation and gender identity following federal directive + 34 more stories

Biotech & Pharma Updates | January 29 - 30, 2025
Vertex scores FDA approval for non-opioid pain alternative, Merck & Co. halts Winrevair Ph3 early after stellar results & offers med to all 172 trial participants, Blackstone's raised $1.6B thus far of mammoth of $5B+ life science-focused fund, Rentschler exits the CGT market, a Republican senator expresses concerns over RFK Jr.'s anti-vax rhetoric + 34 more stories

Biotech & Pharma Updates | January 28 - 29, 2025
Trump administration quickly reverses federal grant freeze after nationwide chaos, 8VC (with interests in life science and healthcare) targets a $1B Fund VI, Lonza on the look-out for M&A to expand biologics capacity and diversify offerings, CARGO Therapeutics stock collapses after scuttling Ph2 trial of firi-cel due to safety concerns and limited durability + 36 more stories

Biotech & Pharma Updates | January 27 - 28, 2025
Helicore Biopharma launches with $65M to develop antibody for “higher-quality” weight loss, Novo Nordisk's Ozempic scores FDA approval for adults with kidney disease and type 2 diabetes, Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT) delivers positive Ph2a data in alcohol use disorder patients, Atara Biotherapeutics to lay off 50% of workforce by June following FDA double tap of Ebvallo rejection and clinical asset holds + 33 more stories

Biotech & Pharma Updates | January 26 - 27, 2025
Sarepta's Elevidys gene therapy delivers positive Ph3 results in Duchenne muscular dystrophy, a pulitzer-prize winning cancer physician + a LinkedIn co-founder join forces (with a $24.6M seed raise) to launch an AI-powered drug discovery engine (Manas AI), Allakos' AK006 flops in Ph1 chronic spontanous urticaria trial, CDC abruptly halts all collaboration with the WHO thus scuttling any hopes of a transition period + 22 more stories

Biotech & Pharma Updates | January 23 - 26, 2025
Chaos amongst US public health and research agencies, Novo Nordisk gets a boost on next-gen obesity hopeful's amycretin Ph1b/2a data, Aardvark Therapeutics files IPO to fund development of obesity drug candidates, Merck & Co. and Eisai's Keytruda + Lenvima combo (partially) flops in gastroesophageal cancer treatment Ph3 + 28 more stories

Biotech & Pharma Updates | January 22 - 23, 2025
Retro Biosciences aiming for a $1B fundraise, AstraZeneca invests CAD 820M ($572M) in expanding Toronto operations site + creating 700 jobs, another Chinese drug developer (Ab&B Bio-Tech) files for a Hong Kong IPO, Teva Pharmaceuticals’ Copaxone gets a black-box safety warning due to severe allergic reaction risk + 21 more stories
